Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Spada F
Authors: Spada F, Laskaratos F, Crona J, Oleinikov K, Zandee W,
Keywords: Carcinoid Heart Disease, NETs, Carcinoid Syndrome, Midgut NETs,
#2122 Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?
Introduction: Quality of life (QoL) is important to all cancer patients. The EORTC QLQ-QNET21 is the most commonly used questionnaire in patients with neuroendocrine tumors (NETs).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: van Leeuwaarde R
Authors: Van Leeuwaarde R, Spada F, Cheung W, Gonzalez-Clavijo A, Pracht M,
Keywords: Quality of life, GEP-NET, EORTC QLQ-GINET21,
Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,
Keywords: SSA high dose,
Introduction: More than 10% of patient treated with Everolimus develop early onset of resistance. The lacking of adequate predictive factors in the targeted hera makes challenging the early identification of non-responders patients.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: cella c
Authors: Cella C, Spada F, Labanca V, Radice D, Rubino M,
Keywords: pancreatic nets, biomarker, everolimus,
#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors
Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Berardi R
Authors: Berardi R, Torniai M, Pusceddu S, Spada F, Brizzi M,
Keywords: pNET, dose intensity, targeted therapy, everolimus, cumulative dose,